Nymox near completion of new NX-1207 follow-up study for BPH

Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH). Nymox expects to report final results and statistical analysis for the study in the next 1-2 weeks. The new study concerns assessment of the 48-60 month efficacy and benefits of a single treatment of NX-1207. Patients in the new study were followed and have remained blinded subsequent to their participation in Nymox's U.S. Study NX02-0014 in 2005-2006.

In the initial study's intent-to-treat cohort after 90 days, patients receiving the 2.5 mg dose of NX-1207 had a mean BPH Symptom Score improvement of 11.0 points, which was significantly better than the improvement shown by the placebo control group (p<.01). There were no significant side effects from NX-1207 in the trial. The initial study was undertaken in 2005-2006 at 43 U.S. sites and enrolled 175 subjects. The new study includes results from all currently available patients.

In multicenter U.S. clinical trials to date NX-1207 has been found to produce improvements in BPH symptom score that are approximately double that reported for currently approved BPH drugs without the side effects associated with those drugs, which can include sexual dysfunction, blood pressure changes and other adverse reactions. Results of follow-up studies of available subjects from NX-1207 clinical trials have provided evidence of durable benefits from NX-1207 treatment for up to 6½ years from the date of treatment.

SOURCE Nymox Pharmaceutical Corporation